FDA Approves Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
The US Food and Drug Administration has approved daraxonrasib, marketed as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment or are not candidates for multiagent therapy. The decision creates a new option for a difficult-to-treat stage of pancreatic cancer, but it is not a general first-line approval or a cure.
The approval is based on RASolute 302, an open-label randomised trial involving 500 patients. Participants were assigned equally to daraxonrasib or a standard treatment selected by their physician.
Survival results in the trial
Median overall survival was 13.2 months for patients receiving daraxonrasib and 6.7 months for the comparison group. The reported hazard ratio for death was 0.40, indicating a substantially lower risk during the study period, although a hazard ratio should not be interpreted as a guarantee for an individual patient.
Median progression-free survival was 7.2 months with the drug and 3.6 months with physician-selected therapy, with a hazard ratio of 0.49. The objective response rate was 30 per cent in the daraxonrasib group and 11 per cent in the control group.
These results describe the trial population and follow-up, not every person with pancreatic cancer. Treatment history, performance status, tumour biology, other illnesses and access to specialist care can change the expected benefit and risk.
Important safety warnings
The FDA information lists serious risks including skin and soft-tissue toxicity, inflammation and other disorders of the mouth, diarrhoea, gastrointestinal perforation and interstitial lung disease or pneumonitis. The drug can also harm a developing fetus.
Patients should urgently report severe abdominal pain, breathing difficulty, a new or worsening cough, fever, severe diarrhoea or extensive skin reactions. Oncologists may need to interrupt treatment, reduce the dose or stop it, depending on the toxicity. Patients should not alter dosing without clinical advice.
The recommended adult dose is 300 milligrams by mouth once daily until the cancer progresses or side effects become unacceptable. Prescribing decisions require a qualified oncology team with access to the complete label, drug-interaction information and appropriate monitoring.
Regulatory scope and next questions
The FDA completed its review about six and a half months ahead of the agency’s target date. It worked through Project Orbis with Health Canada, while European and Japanese regulators participated as observers. A US approval does not mean the medicine is automatically approved in Canada, India, Europe or Japan; each regulator makes its own decision.
Future evidence should clarify durability of response, quality of life, performance in broader patient groups and how the drug compares with evolving treatment combinations. Cost and availability will also determine whether a statistically meaningful advance becomes accessible in routine care.
For patients and families, the central message is specific: daraxonrasib offers a validated new option after previous treatment or when multiagent therapy is unsuitable. Whether it is appropriate for an individual requires a discussion with the treating oncologist, not self-medication or conclusions drawn from headline survival figures alone.
